Disease progression and the risk factor analysis for chronic hepatitis C

Liver International

Volumn 28, Issue 10, 2008, Pages 1363-1369

  Sinn, Dong Hyun ^a   Paik, Seung Woon ^a   Kang, Pung ^a   Kil, Jae Sook ^a   Park, Sang Un ^a   Lee, So Young ^a   Song, Soon Mi ^a   Gwak, Geum Youn ^a   Choi, Moon Seok ^a   Lee, Joon Hyoek ^a   Koh, Kwang Cheol ^a   Yoo, Byung Chul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Disease progression; Hepatitis C virus; Hepatocellular carcinoma; Risk factor

Indexed keywords

ASPARTATE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL PERITONITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ESOPHAGUS HEMORRHAGE; FATALITY; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT MONITORING; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STOMACH HEMORRHAGE; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; KOREA; LIVER CIRRHOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 54049158505     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01860.x     Document Type: Article

References (25)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
4. Sullivan DG, Bruden D, Deubner H, et al. Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease. J Infect Dis 2007; 196: 239-48.
5. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen-year prospective cohort study. Hepatology 2007; 46: 1350-6.
6. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
7. Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425-30.
8. Huang JF, Yu ML, Lee CM, et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: A 1,386-patient study from Taiwan. Aliment Pharmacol Ther 2007; 25: 1029-37.
9. Fattovich G, Llovet JM. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: What we know and what is missing. J Hepatol 2006; 44: 1013-6.
10. Lawson A, Hagan S, Rye K, et al. The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol 2007; 47: 37-45.
11. Park JW. [Practice guideline for diagnosis and treatment of hepatocellular carcinoma]. Korean J Hepatol 2004; 10: 88-98.
12. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
13. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
14. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16.
15. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: A prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-9.
16. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-10.
17. Tazawa J, Maeda M, Nakagawa M, et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 710-5.
18. Shindo M, Ken A, Okuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999; 85: 1943-50.
19. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760-4.
20. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.
21. Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10: 285-93.
22. Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995; 90: 1250-7.
23. Luo JC, Hwang SJ, Lai CR, et al. Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan. J Gastroenterol Hepatol 1998; 13: 685-90.
24. Lin CS, Chang CS, Yang SS, Yeh HZ, Lin CW. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Intern Med 2008; 47: 569-75.
25. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: A systematic review. Hepatology 2007; 46: 912-21.